Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 5/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.54 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP4 | P49662 | 1/20 | 0.49 |
| ▸ | CASP5 | P51878 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2767436 | 0.85 | HSP90AA1 (0.57) | ADRA1DADRA1AADRA1BHTR1ADRD2 | |
| SCHEMBL2765952 | 0.84 | MEN1 (0.61) | ADRA1DADRA1AADRA1BHTR1ADRD2 | |
| SCHEMBL2767637 | 0.84 | HTR1A (0.54) | ADRA1DADRA1AADRA1BHTR1ADRD2 | |
| SCHEMBL2767088 | 0.82 | HTR1A (0.51) | ADRA1DADRA1AADRA1BHTR1ADRD2 | |
| SCHEMBL2768032 | 0.81 | ADRA1D (0.61) | ADRA1DADRA1AADRA1BHTR1ASIGMAR1 | |
| SCHEMBL2766366 | 0.77 | HTR1A (0.78) | HTR1ADRD2OPRM1ALDH1A1HTR7 | |
| SCHEMBL23244347 | 0.76 | KMT2A (0.72) | MEN1ALDH1A1KMT2A | |
| SCHEMBL29576156 | 0.76 | KMT2A (0.72) | MEN1ALDH1A1KMT2A | |
| SCHEMBL2766286 | 0.76 | HTR1A (0.61) | HTR1ADRD2OPRM1SIGMAR1 | |
| SCHEMBL2766148 | 0.75 | ADRA1D (0.68) | ADRA1DADRA1AADRA1BHTR1ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888584-B1 | 1, 6 -DIHYDRO- 1,3, 5, 6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AS INHIBITORS OF IKK ENZYME ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2010-04-21 | — | — | EP | disclosed |
| EP-1627871-B1 | CYCLIC AMINOPHENYL SULFAMATE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2010-04-14 | — | — | EP | disclosed |
| US-7449466-B2 | Cyclic aminophenyl sulfamate derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2008-11-11 | — | — | US | disclosed |
| US-20060189625-A1 | Cyclic aminophenyl sulfamate derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| EP-1627871-A1 | CYCLIC AMINOPHENYL SULFAMATE DERIVATIVE | Teikoku Hormone Mfg. Co., Ltd. (JP) | 2006-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189625-A1 | Cyclic aminophenyl sulfamate derivative | SHBG, STS, ARSA | ADRA1D 2006/4885ADRA1A 2425/4885ADRA1B 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.